{"prompt": "['7.', 'VISIT SCHEDULE AND ASSESSMENTS', '7.1.', 'Study Visit Schedule and Assessments', 'A list of all study assessments is included in Table 3, which indicates with an \"X\" if the', 'assessment performed at that visit.', 'The Screening (Visit 1) evaluation should be performed VI 30 days prior to Treatment (Visit 3).', 'Additional screening will be performed at Baseline (Visit 2), not less than 7 days prior to', 'Treatment (Visit 3).', 'Study visits, tests and/or procedures should occur on schedule per Table 3. Any exceptions will', 'have to be approved by the sponsor.', 'Page 30 of 101']['Table 3:', 'Visit Schedule and Assessments', 'Visit', 'Visit 1', 'Visit 2', 'Visit 3', 'Visit 4', 'Visit 5', 'Visit 6', 'Treatment', 'Screening Period', 'Period', 'Post-Treatment Follow-up Peirod', 'Screening', 'Baseline', 'Treatment', 'Week 1', 'Week 6', 'Week 12', '-30 to -7', '-10 to -7', 'Day 7', 'Day 42', 'Day 84', 'Study Day(s)', 'Day 1', '(=2 days)', '(=5 days)', '(7 days)', 'Informed Consent', 'X', 'Inclusion/Exclusion criteria', 'X', 'Medical History', 'X', 'Diagnosis and Extent', 'X', 'incompetent saphenous vein', 'Demographics', 'X', 'Physical Exam', 'X', 'X', 'Pregnancy test (serum)', 'X', 'Pregnancy test (urine)', 'X', 'X', 'Height', 'X', 'Weight', 'X', 'Vital signs', 'X', 'X', 'X', 'X', 'X', 'X', 'Hematological Assessment', 'X', 'X', 'X', 'X', 'Intravascular Coagulation', 'X', 'X', 'X', 'X', 'Assessmentb c', 'X', 'Adverse events', 'X', 'Continuous', 'Concomitant medications', 'X', 'Continuous', 'and Non-Drug procedures', 'Ultrasound', 'X', 'X', 'X', 'X', 'X', 'X', 'CEAP Classification', 'X', 'X', 'rVCSS', 'X', 'X', 'HASTI symptoms - 7-day', 'X', 'X', 'X', 'X', 'assessment', 'European Quality of Life', 'X', 'X', 'X', 'X', 'X', 'scale (EQ-5D-5L)', 'VEINES-QOL-SYM', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'VAS score', '(Procedure only)', 'X', 'ClariVein RES procedure', 'a Hematological Assessments include: Hemolysis, hematocrit, reticulocyte count, haptoglobins as described in', 'Section 8.1', 'b Intravascular coagulations include Plasma fibrinogen level, Plasma D-dimer level platelet count, Prothrombin', 'time (PT), Partial thromboplastin time (PTT) as described in Section 8.1.', 'c Plasma D-dimer level assessments will be conducted at: Baseline (Visit 2 2) immediately post Treatment (Visit 3)', 'and at Week 1 follow-up (Visit 4); then, only at subsequent follow-up visits [Week 6 (Visit 5) and Week 12 (Visit', '6) if the D-dimer level is higher than it was at Baseline.', 'Page 31 of 101']['7.2.', 'Pre-visit Patient Instructions', 'When scheduling a patient for a study visit, advise the patient to be mobile for at least 2 to', '3', 'hours prior to arriving at the Investigational Study Site; this will facilitate obtaining precise', 'measurements of incompetent saphenous vein.', 'Refer to the Appendix C VICARES Clinical Study Procedure Manual for instruction on the', 'preparation and ultrasound procedure', '7.3.', 'Screening (Visit 1)', 'The study IRB approved informed consent form must be signed and dated before any screening', 'procedures are performed, except for any laboratory tests performed as part of standard of care', 'within the study screening window.', 'Patients will be evaluated against study inclusion and exclusion criteria. Patients must meet all', 'inclusion and none of the exclusion criteria at Screening to be eligible for the study. For details', 'of assessments, refer to Table 3.', 'At the Investigational site, prior to ultrasound assessment of the venous system, the patient will', 'be asked to stand or walk for 10-15 minutes.', 'During Screening visit (Visit 1), the Investigator/Investigational Staff will:', '1. Perform all Visit 1 assessments per Table 3', '2. At the end of the Screening Visit, if the patient fails to be eligible per the', 'Inclusion/Exclusion criteria, the patient will be considered a screen failure and the', 'reason for failure must be documented in the screening log.', '7.4.', 'Baseline (Visit 2)', 'The Baseline visit will occur - 10 to 7 days prior to the Day of Treatment.', 'At the Investigational site, prior to ultrasound assessment of the incompetent saphenous vein,', 'the patient will be asked to stand or walk for 10-15 minutes.', 'During the Baseline visit (Visit 2), the Investigator/Clinical Study Staff will:', '1. Perform all Visit 2 assessment per Table 3.', '2. Review the preliminary ultrasound mapping of the bilateral superficial venous systems', 'and the selected incompetent saphenous vein (which was obtained during the initial', 'Screening (Visit 1)', '3. Perform unilateral ultrasound imaging studies of the incompetent saphenous vein', 'selected for treatment with patient in the standing position to determine:', 'a.', 'access site (e.g., lowest point of reflux, as appropriate); and', 'b. treatment section length (TSL) and treatment section diameter (TSD) measurements.', '4. Review the VEINES-QOL Sym with the patient. Instruct patient to answer the HASTI', 'Symptom questions for 7-consecutive days prior to the arrival at the Day of Treatment', 'visit (Visit 3).', 'Page 32 of 101']\n\n###\n\n", "completion": "END"}